CUSIP: 62921N105
Q2 2019 13F Holders as of 30 Jun 2019
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
26,070,117
-
Share change
-
+26,070,085
-
Total reported value
-
$381,660,468
-
Price per share
-
$14.64
-
Number of holders
-
46
-
Value change
-
+$381,660,000
-
Number of buys
-
45
Quarterly Holders Quick Answers
What is CUSIP 62921N105?
CUSIP 62921N105 identifies NGM - NGM BIOPHARMACEUTICALS INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 62921N105:
Institutional Holders of NGM BIOPHARMACEUTICALS INC - COM (NGM) as of Q2 2019
As of 30 Jun 2019,
NGM BIOPHARMACEUTICALS INC - COM (NGM) was held by
46 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
26,070,117 shares.
The largest 10 holders included
Svennilson Peter, RHO CAPITAL PARTNERS INC, Greenspring Associates, LLC, ROYAL BANK OF CANADA, Foresite Capital Management IV, LLC, Rock Springs Capital Management LP, Jasper Ridge Partners, L.P., HealthCor Management, L.P., BlackRock Inc., and EcoR1 Capital, LLC.
This page lists
46
institutional shareholders reporting positions in this security
for the Q2 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.